Han Sheng-jin, Xu Ge-liang, Jia Wei-dong, Wang Yong-cang, Li Jian-sheng, Ma Jin-liang, Ren Wei-hua, Ge Yong-sheng, Liu Wen-bin, Zhang Chuan-hai, Wang Wei
Centre for the Study of Liver Cancer, Department of Hepatic Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China.
Zhonghua Wai Ke Za Zhi. 2010 Dec 15;48(24):1875-80.
To investigate the expression and its clinical significance of estrogen receptor (ERα) and phosphorylated estrogen receptor (p-ERα) in patients with hepatocellular carcinoma. The associations between ERα, p-ERα and IL-6 were also analyzed.
Immunohistochemistry was used to detect the expression of ERα, p-ERα and IL-6 in tumor tissues from 77 cases with hepatocellular carcinoma. The relations between ERα and the clinical pathological parameters and prognosis were also analyzed.
The positive rates of ERα, p-ERα and IL-6 in hepatocellular carcinoma were 39.0% (30/77), 45.4% (35/77) and 72.7% (56/77), respectively. The expression of ERα and p-ERα were negatively correlated with the expression of IL-6 (r=-0.468, P<0.01; r=-0.370, P<0.01, respectively). The positive rate of ERα in patients with tumor size≤5 cm, serum level of alpha-fetoprotein<400 µg/L, with complete encapsulation and non-microvascular invasion was significantly higher than those with tumor size>5 cm, serum level of alpha-fetoprotein≥400 µg/L, non-complete encapsulation and with microvascular invasion (all P<0.05). The overall survival rates of ERα-positive and ERα-negative patients were 66.7% and 23.4% (P<0.05). And the disease-free survival rates of ERα-positive and ERα-negative patients were 83.3% and 57.4% (P<0.05).
The tumor biological features of ERα-positive patients are better than that of ERα-negative patients. The role of ERα in hepatocellular carcinoma may be related to IL-6 level.
探讨雌激素受体（ERα）及磷酸化雌激素受体（p-ERα）在肝细胞癌患者中的表达及其临床意义。同时分析ERα、p-ERα与白细胞介素-6（IL-6）之间的相关性。
采用免疫组织化学法检测77例肝细胞癌患者肿瘤组织中ERα、p-ERα及IL-6的表达。分析ERα与临床病理参数及预后的关系。
肝细胞癌中ERα、p-ERα及IL-6的阳性率分别为39.0%（30/77）、45.4%（35/77）和72.7%（56/77）。ERα和p-ERα的表达与IL-6的表达呈负相关（r分别为-0.468，P<0.01；r为-0.370，P<0.01）。肿瘤大小≤5 cm、血清甲胎蛋白水平<400 μg/L、有完整包膜且无微血管侵犯患者的ERα阳性率显著高于肿瘤大小>5 cm、血清甲胎蛋白水平≥400 μg/L、包膜不完整且有微血管侵犯的患者（均P<0.05）。ERα阳性和ERα阴性患者的总生存率分别为66.7%和23.4%（P<0.05）。ERα阳性和ERα阴性患者的无病生存率分别为83.3%和57.4%（P<0.05）。
ERα阳性患者的肿瘤生物学特征优于ERα阴性患者。ERα在肝细胞癌中的作用可能与IL-6水平有关。
